Effect of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogels on frozen-thawed human ovarian tissue in a xenograft model

2018 ◽  
Author(s):  
Ayaka Tanaka ◽  
Hitomi Nakamura ◽  
Yasuhiko Tabata ◽  
Yuka Fujimori ◽  
Keiichi Kumasawa ◽  
...  
Keyword(s):  
Growth Factor ◽  
Sustained Release ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Ovarian Tissue ◽  
Xenograft Model ◽  
Fibroblast Growth ◽  
Human Ovarian Tissue

Aluminium β-Cyclodextrin Sulphate as a Stabilizer and Sustained-release Carrier for Basic Fibroblast Growth Factor

1994 ◽  
Vol 46 (3) ◽  
pp. 168-171 ◽  
Author(s):  
KAZUHIRO FUKUNAGA ◽  
SHIGEKI HIJIKATA ◽  
KIMIHIRO ISHIMURA ◽  
RYOUICHI SONODA ◽  
TETSUMI IRIE ◽  
...  
Keyword(s):  
Growth Factor ◽  
Sustained Release ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Fibroblast Growth

scholarly journals Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo

Nanomaterials ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. 1037 ◽  
Author(s):  
Pala Arunkumar ◽  
Julie A. Dougherty ◽  
Jessica Weist ◽  
Naresh Kumar ◽  
Mark G. Angelos ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Growth Factor ◽  
Sustained Release ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Angiogenic Factor ◽  
Fibroblast Growth ◽  
Angiogenic Potential

Coronary heart disease (CHD) is the leading cause of death in the Unites States and globally. The administration of growth factors to preserve cardiac function after myocardial infarction (MI) is currently being explored. Basic fibroblast growth factor (bFGF), a potent angiogenic factor has poor clinical efficacy due to its short biological half-life and low plasma stability. The goal of this study was to develop bFGF-loaded polycaprolactone (PCL) microspheres for sustained release of bFGF and to evaluate its angiogenic potential. The bFGF-PCL microspheres (bFGF-PCL-MS) were fabricated using the emulsion solvent-evaporation method and found to have spherical morphology with a mean size of 4.21 ± 1.28 µm. In vitro bFGF release studies showed a controlled release for up to 30 days. Treatment of HUVECs with bFGF-PCL-MS in vitro enhanced their cell proliferation and migration properties when compared to the untreated control group. Treatment of HUVECs with release media from bFGF-PCL-MS also significantly increased expression of angiogenic genes (bFGF and VEGFA) as compared to untreated cells. The in vivo angiogenic potential of these bFGF-PCL-MS was further confirmed in rats using a Matrigel plug assay with subsequent immunohistochemical staining showing increased expression of angiogenic markers. Overall, bFGF-PCL-MS could serve as a potential angiogenic agent to promote cell survival and angiogenesis following an acute myocardial infarction.

Sign in / Sign up

Export Citation Format

Share Document